Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0016632 (Fox)
 1,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This important conference focused on the latest developments in therapeutic antibodies, particularly for their design, production and formulation for cancer therapy. Engineered antibodies currently represent over 30% of biopharmaceuticals in clinical trials, highlighted by the recent FDA approvals of Zevalin (ibritumomab tiuxetan, IDEC Pharmaceuticals) for cancer radioimmunotherapy and Humira (adalimumab, Abbott Laboratories) for rheumatoid arthritis [1,2]. An impressive array of international speakers was assembled in Banff by the organisers L Weiner (Fox Chase Cancer Center, USA) and P Carter (Amgen and Seattle Genetics). The meeting highlighted emerging new technologies, both for the discovery of novel cancer biomarkers and for innovative immunotherapeutic designs. The latest successes were also presented for antibodies directed to the conventional cancer targets, including CD20, carcinoembryonic antigen (CEA), erbB-family proteins and vascular endothelial growth factor (VEGF). Importantly, recent structural details emerged that will direct future designs of these cancer-targeting molecules, ranging from antibody-dependent cellular-cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) enhancement to improved cytotoxic payloads using radionuclides, toxins, enzymes, drugs and viral delivery. The conference also highlighted the latest in vitro antibody libraries for the selection of high-affinity reagents against refractory cancer targets, and included the design of small domain modules for highly-efficient in vivo targeting to large, high avidity complexes for enhanced cytotoxicity. The major challenges in this rapidly growing area include the need to initiate and sustain innate and adaptive immune responses for the generation of efficient, long-term tumour therapy. This conference was sponsored by Amgen and accredited by the Accreditation Council for Continuing Medical Education (ACCME).
 ...
PMID:Keystone symposia: antibody-based therapeutics for cancer. 1266 51

The paclitaxel/carboplatin combination has demonstrated promising activity in metastatic non-small-cell lung cancer (NSCLC); therefore, we mounted an exploratory study of these agents with thoracic radiation (TRT) in locally advanced NSCLC. Eligibility stipulated a Karnofsky performance status >or= 70%, weight loss <or= 5%, and primarily stage IIIB or bulky IIIA NSCLC. Induction chemotherapy (CT), 2 cycles of paclitaxel 175-225 mg/m2 over 3 hours and carboplatin (targeted area under the curve [AUC] of 7.5), was administered on days 1 and 22. Granulocyte colony-stimulating factor (G-CSF) 5 microg/kg was given on days 2-15 and 23-36 to all patients; half were randomized to priming G-CSF every day x 5 prior to day 1 of induction therapy. On day 43, TRT (60-63 Gy/30-34 fx) was initiated. At dose level 1, only Fox Chase Cancer Center patients received carboplatin (initial target AUC 3.75) and paclitaxel (67.5 mg/m2 over 3 hours) days 43 and 64. In the absence of dose-limiting toxicity, phase I dose escalation in 3-patient cohorts was scheduled to proceed to a maximum carboplatin AUC 7.5 and paclitaxel dose of 210 mg/m2. To date, 53 patients have received induction therapy; 4 are too early to evaluate. The portion of the study evaluating G-CSF priming revealed no myeloprotective effect, likely due to a lack of myelosuppressive toxicity with the conventionally dosed cohort. Twenty-two patients have received concurrent TRT/CT. In sequential cohorts, the chemotherapy doses on days 43 and 64 have been escalated (to paclitaxel 175 mg/m2 and carboplatin AUC 5) with 1 episode each of grade 4 granulocytopenia and grade 3 anemia. The occurrence of grade >or= 2 esophagitis has corresponded to length (> 16 cm) of esophagus in the radiation treatment field (Fisher's exact test, P = 0.006). The partial response rate to induction therapy was 40% and to the combined modality therapy was 60%. The median survival for all 49 patients is 15.3 months, with a median disease-free survival (DFS) of 7.8 months. In the subset of 22 patients treated on the phase I portion of the study, the median survival and DFS were 18.5 months and 13.5 months, respectively. Induction therapy with paclitaxel and carboplatin followed by concurrent chemoradiotherapy with the same agents is an active and well-tolerated treatment approach in locally advanced NSCLC. To date, paclitaxel 175 mg/m2 plus carboplatin AUC 5 administered at 3-week intervals for 2 cycles is safe in combination with TRT.
 ...
PMID:Induction and concurrent paclitaxel/carboplatin every 3 weeks with thoracic radiotherapy in locally advanced non-small-cell lung cancer: an interim report. 1465 27

Around the world, traditionally the diagnosis of cancer and its prognosis was withheld from patients for centuries, due to the stigma and fears attached to it. This custom of 'never telling' precluded talking with patients about their feelings and how they were coping with illness and the threat of death. In the last quarter of the twentieth century, patient's right of access to information, coupled with the diminished stigma attached to cancer, encouraged physicians into a more open dialogue. In the majority of countries today, patients learn their diagnosis and know their treatment options. This change permitted the first formal psychosocial studies of patients in the 1950s, and the beginning of research into coping and development of interventions to improve quality of life. However, a second independent stigma, also present for centuries, has persisted: the stigma associated with mental disorders (even in the context of severe physical illness). This prejudice about mental problems has been a barrier to the integration of the psychosocial domain into total cancer care; the identification of patients who are distressed; and, patient's acceptance of psychological help. Despite these barriers, psychosocial oncology has developed worldwide, with a small, but active cadre of investigators and clinicians engaging in clinical, educational and research aspects of psycho-oncology. The International Psycho-Oncology Society (IPOS), since 1984, has brought them together. The Sutherland Memorial Lecture has honored nine individuals from five countries who have made major contributions to the field: 1982, Avery Weisman; 1984, Bernard Fox; 1987, Morton Bard; 1991, Margit von Kerekjarto; 1993, Ned Cassem; 1996, Steven Greer; 1998, Hiroomi Kawano; 2000, Robert Zittoun; and 2003, Jimmie Holland. The scientific base for psychosocial oncology is now secure with a body of knowledge, textbooks and journals which have led to the development of evidence-based clinical practice guidelines for psychosocial services in several countries. A benchmark now exists against which care can be monitored and accountability established. The next 25 years will see an improvement in the psychosocial care of patients, based on research that gives a scientific basis for interventions, and a reduction in the barriers to psychosocial care in cancer.
 ...
PMID:IPOS Sutherland Memorial Lecture: an international perspective on the development of psychosocial oncology: overcoming cultural and attitudinal barriers to improve psychosocial care. 1522 14

In his best known contribution to the field of psychooncology, the late Dr Bernard H. Fox applied his breadth of scholarship in biopsychosocial cancer epidemiology to address the question of whether and to what extent stress and other psychosocial factors may contribute to cancer risk. Less well known but equally important to the field is his incisive critique of the 1989 study by Spiegel et al. on survival time of patients with metastatic breast cancer following a psychosocial intervention. This essay represents an attempt to take Fox's line of thought to the next logical level of rethinking research on psychosocial interventions in biopsychosocial oncology. Following an analysis of the inadequacy of randomized clinical trials (RCT) to evaluate the causal effects of psychosocial interventions on cancer outcomes and distinguish these from mere prediction, an integrated RCT design is suggested to take into account the psychogenicity of a given intervention, potential mediating mechanisms, and individual differences that could help illuminate hypothesized causal processes linking an experimental intervention and cancer outcomes.
 ...
PMID:Rethinking research on psychosocial interventions in biopsychosocial oncology: an essay written in honor of the scholarly contributions of Bernard H. Fox. 1522 15

Although quality of life is extensively defined as subjective and multidimensional with both affective and cognitive components, few instruments capture important dimensions of the construct, and few are both conceptually congruent and user friendly for the clinical setting. The aim of this study was to develop and test a measure that would be easy to use clinically and capture both cognitive and affective components of quality of life. Initial item sources for the Fox Simple Quality-of-Life Scale (FSQOLS) were literature-based. Thirty items were compiled for content validity assessment by a panel of expert healthcare clinicians from various disciplines, predominantly nursing. Five items were removed as a result of the review because they reflected negatively worded or redundant items. The 25-item scale was mailed to 177 people with lung, colon, and ovarian cancer in various stages. Cancer types were selected theoretically, based on similarity in prognosis, degree of symptom burden, and possible meaning and experience. Of the 145 participants, all provided complete data on the FSQOLS. Psychometric evaluation of the FSQOLS included item-total correlations, principal components analysis with varimax rotation revealing two factors explaining 50% variance, reliability estimation using alpha estimates, and item-factor correlations. The FSQOLS exhibited significant convergent validity with four popular quality-of-life instruments: the Ferrans and Powers Quality of Life Index, the Functional Assessment of Cancer Therapy Scale, the Short-Form-36 Health Survey, and the General Well-Being Scale. Content validity of the scale was explored and supported using qualitative interviews of 14 participants with lung, colon and ovarian cancer, who were a subgroup of the sample for the initial instrument testing.
 ...
PMID:Preliminary psychometric testing of the Fox Simple Quality-of-Life Scale. 1523 15

We applied MRI to the in vivo detection of spontaneous colorectal tumors in a unique mouse model, the Fox Chase Cancer Center (FCCC) ApcMIN mouse. Unlike other Min (multiple intestinal neoplasia) strains, FCCC ApcMIN animals develop an appreciable number of tumors in the large intestine, which makes them an appropriate mouse model for colon cancer in humans. We describe a method for marking the colon on MRI data sets that involves a bowel-cleansing procedure and the insertion of a polyurethane tube (filled with an MRI contrast agent) fully into the colon. We found that tumors as small as 1.5 mm in diameter can be consistently identified from MRI datasets with a voxel size of 0.1 mm x 0.133 mm x 0.133 mm. Tumor volumes were determined from the MRM data sets with the use of a novel approach to planimetry in 3D data sets. We observed a correlation between tumor volume (as measured from the MRI datasets) and tumor weight of 0.942, and a P-value of 0.008, based on Spearman's test. These data show that MRI can be used to accurately monitor tumor growth in mouse models of colorectal carcinogenesis.
 ...
PMID:Detection and volume determination of colonic tumors in Min mice by magnetic resonance micro-imaging. 1533 70

This article reviews the Fox Chase Cancer Center experience of preoperatively and postoperatively delivered adjuvant chemotherapy and radiation therapy for localized adenocarcinoma of the pancreas.
 ...
PMID:Preoperative chemoradiation therapy for adenocarcinoma of the pancreas: The Fox Chase Cancer Center experience, 1986-2003. 1535 Sep 42

Fifty years ago, the Eker rat was identified as the first animal model of hereditary renal adenoma and carcinoma, with histopathology resembling human renal carcinoma. Ten years ago, a mutation in the TSC2 gene was identified in the Eker rat at Fox Chase Cancer Center by Yeung and Knudson, and in Tokyo by Kobayashi and Hino. The literature contains dozens of reports of renal cell carcinoma (RCC) in tuberous sclerosis complex (TSC) patients, including tumors in children as young as five and one report in an infant. Despite these facts, the association between TSC and RCC is under-recognized, and sometimes completely omitted from discussions of inherited renal carcinoma. Here, we will review the clinical association of RCC in TSC, consider the factors that have led to its under-emphasis within the RCC field, address the cellular and biochemical mechanisms that may contribute to RCC in cells with TSC1 or TSC2 mutations, and finally discuss the ways in which the TSC signaling pathways may be linked to sporadic RCC in the general population.
 ...
PMID:The genetic basis of kidney cancer: why is tuberous sclerosis complex often overlooked? 1557 29

The forkhead (Fox) gene family comprises a diverse group of "winged-helix" transcription factors that play important roles in development, metabolism, cancer and aging. Recently, several forkhead genes have been demonstrated to play critical roles in lymphocyte development and effector function, including Foxp3 in the development of regulatory T cells, Foxj1 and Foxo3a in the regulation of CD4+ T cell tolerance, and Foxn1 in thymic development. Roles for other forkhead genes have also been proposed, including Foxp1 in macrophage differentiation, Foxq1 in natural killer cell effector function and Foxd2 in T cell activation. Thus, forkhead genes promise insight into the mechanisms of immunoregulation in several immune cell lineages, and their dysregulation likely contributes to the pathogenesis of several immunological disorders, suggesting that their study will lead to the development of novel therapeutic agents.
 ...
PMID:Forkhead transcription factors in immunology. 1571 67

My interest in protein breakdown as a research problem began in 1955. In 1963, when we relocated from Yale to the Institute for Cancer Research of Fox Chase, Philadelphia, nothing new was being reported. Here, I review how we get the ubiquitin proteasome system all together.
 ...
PMID:Ubiquitin at Fox Chase. 1609 96


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>